Clinical Significance of MET Gene Copy Number in Patients with Curatively Resected Gastric Cancer / 전남의대학술지
Chonnam Medical Journal
; : 81-85, 2015.
Article
de En
| WPRIM
| ID: wpr-121246
Bibliothèque responsable:
WPRO
ABSTRACT
The present study analyzed the prognostic impact of MET gene copy number in patients with curatively resected gastric cancer who received a combination regimen of cisplatin and S-1. The MET gene copy number was analyzed by use of quantitative real-time polymerase chain reaction. From January 2006 to July 2010, 70 tumor samples from 74 patients enrolled in a pilot study were analyzed. According to a cutoff MET gene copy number of > or =2 copies, a high MET gene copy number was observed in 38 patients (54.3%). The characteristics of the 2 groups divided according to MET gene copy number were similar. With a median follow-up duration of 26.4 months (range, 2.6-73.2 months), the estimated 3-year relapse-free survival and overall survival rates were 54.3% and 77.4%, respectively. No significant association was observed between the MET gene copy number and survival in a multivariate analysis. The MET gene copy number investigated in this study was not found to be associated with prognosis in patients with curatively resected gastric cancer.
Mots clés
Texte intégral:
1
Indice:
WPRIM
Sujet Principal:
Pronostic
/
Tumeurs de l'estomac
/
Projets pilotes
/
Analyse multifactorielle
/
Taux de survie
/
Études de suivi
/
Cisplatine
/
Traitement médicamenteux adjuvant
/
Dosage génique
/
Réaction de polymérisation en chaine en temps réel
Type d'étude:
Observational_studies
/
Prognostic_studies
Limites du sujet:
Humans
langue:
En
Texte intégral:
Chonnam Medical Journal
Année:
2015
Type:
Article